```
=> fil reg
FILE 'REGISTRY' ENTERED AT 07:05:22 ON 28 JUL 1999
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1999 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:   28 JUL  99  HIGHEST RN 229185-84-6
DICTIONARY FILE UPDATES:  28 JUL  99  HIGHEST RN 229185-84-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 13, 1999

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

=> d stat que l16
L1              STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  37

STEREO ATTRIBUTES: NONE
L3          2288 SEA FILE=REGISTRY SSS FUL L1
L4               STR
```



NODE ATTRIBUTES:
CONNECT IS M1 RC AT 36
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 38

STEREO ATTRIBUTES: NONE
L6 806 SEA FILE=REGISTRY SUB=L3 CSS FUL L4
L9 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 38

STEREO ATTRIBUTES: NONE
L11 128 SEA FILE=REGISTRY SUB=L6 CSS FUL L9
L12 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 4

STEREO ATTRIBUTES: NONE
L14 436 SEA FILE=REGISTRY SUB=L6 SSS FUL L12
L15 13 SEA FILE=REGISTRY ABB=ON PLU=ON L11 AND L14
L16 1 SEA FILE=REGISTRY ABB=ON PLU=ON L15 AND C5H9NO4

=> d ide can l16

L16 ANSWER 1 OF 1 REGISTRY COPYRIGHT 1999 ACS
RN 111266-56-9 REGISTRY
CN L-Glutamic acid, compd. with (8S,10S)-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-, L-glutamate (salt) (9CI)
CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-, L-glutamate (salt)
CN L-Glutamic acid, compd. with (8S-cis)-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
OTHER NAMES:
CN Doxorubicin glutamic acid salt
FS STEREOSEARCH
MF **C27 H29 N O11 . x C5 H9 N O4**
SR CA
LC STN Files: CA, CAPLUS, DRUGPAT, TOXLIT, USPATFULL

CM 1

CRN 23214-92-8
CMF C27 H29 N O11

Absolute stereochemistry.



CM 2

CRN 56-86-0
CMF C5 H9 N O4

Absolute stereochemistry.



4 REFERENCES IN FILE CA (1967 TO DATE)
4 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:158335

REFERENCE 2: 127:39845

REFERENCE 3: 110:141560

REFERENCE 4: 107:223275

=> d stat que l19
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 37

STEREO ATTRIBUTES: NONE
L3 2288 SEA FILE=REGISTRY SSS FUL L1
L4 STR



NODE ATTRIBUTES:
CONNECT IS M1 RC AT 36
DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 38

STEREO ATTRIBUTES: NONE
L6 806 SEA FILE=REGISTRY SUB=L3 CSS FUL L4
L7 211 SEA FILE=REGISTRY ABB=ON PLU=ON L6 AND SEQ/FA
L12 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 4

STEREO ATTRIBUTES: NONE
L14 436 SEA FILE=REGISTRY SUB=L6 SSS FUL L12
L17 209 SEA FILE=REGISTRY ABB=ON PLU=ON L7 AND L14
L18 2 SEA FILE=REGISTRY ABB=ON PLU=ON L7 NOT L17
L19 211 SEA FILE=REGISTRY ABB=ON PLU=ON (L7 OR L17 OR L18)

=> d stat que l20
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 37

STEREO ATTRIBUTES: NONE
L3 2288 SEA FILE=REGISTRY SSS FUL L1
L4 STR



NODE ATTRIBUTES:
CONNECT IS M1 RC AT 36
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 38

STEREO ATTRIBUTES: NONE
L6 806 SEA FILE=REGISTRY SUB=L3 CSS FUL L4
L7 211 SEA FILE=REGISTRY ABB=ON PLU=ON L6 AND SEQ/FA
L9 STR



```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  38

STEREO ATTRIBUTES: NONE
L11          128 SEA FILE=REGISTRY SUB=L6 CSS FUL L9
L12              STR
```



```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   4

STEREO ATTRIBUTES: NONE
L14          436 SEA FILE=REGISTRY SUB=L6 SSS FUL L12
L15           13 SEA FILE=REGISTRY ABB=ON  PLU=ON  L11 AND L14
L16            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L15 AND C5H9NO4
L17          209 SEA FILE=REGISTRY ABB=ON  PLU=ON  L7 AND L14
L18            2 SEA FILE=REGISTRY ABB=ON  PLU=ON  L7 NOT L17
L19          211 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L7 OR L17 OR L18)
L20          226 SEA FILE=REGISTRY ABB=ON  PLU=ON  L14 NOT (L16 OR L19)

=>
```

```
=>
=> d his l21-

     (FILE 'HCAPLUS' ENTERED AT 06:53:49 ON 28 JUL 1999)
                E DEFEO JONES D/AU
L21          32 S E3,E4
                E DEFEOJONES D/AU
                E JONES DEFEO/AU
                E FENG D/AU
L22         180 S E3,E8,E10,E91,E92,E94-E96
                E GARSKY V/AU
L23         115 S E3-E7
                E JONES R/AU
L24         636 S E3,E32-E35
                E JONES RAY/AU
L25          41 S E12,E17,E18
                E OLIFF A/AU
L26         117 S E3,E4,E6,E8
L27        1065 S L21-L26
L28          14 S L27 AND ?PROSTAT?
L29          96 S L16,L19,L20
L30           6 S L27 AND L29
                E MERCK/PA,CS
L31       20529 S E3,E4
L32           6 S L29 AND L31
L33           6 S L30,L32

     FILE 'REGISTRY' ENTERED AT 06:59:37 ON 28 JUL 1999
                E DOXORUBICIN/CN
L34           1 S E3
                E METHOTREXATE/CN
L35           1 S E3
                E VINBLASTINE/CN
L36           1 S E3
                E ANTHRACYCLIN/CN

     FILE 'HCAPLUS' ENTERED AT 07:00:05 ON 28 JUL 1999
L37          84 S (L34 OR L35 OR L36 OR DOXORUBICIN? OR METHOTREXAT? OR VINBLAS
L38           9 S L29 AND ?PROSTAT?
L39           9 S L38 AND L37
L40           6 S L38 AND L33
L41           9 S L33,L39,L40
L42       12315 S L6
L43          27 S L42 AND (OLIGOPEPTIDE OR OLIGO(L)PEPTIDE)
L44           7 S L43 AND ?PROSTAT?
L45          10 S L41,L44
L46           6 S L43 AND L27,L31
L47          10 S L45,L46
                SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 07:03:59 ON 28 JUL 1999
L48         152 S E1-E152
L49         149 S L48 NOT L34-L36
L50           0 S L49 AND L16
L51         139 S L49 AND L19
L52           8 S L49 AND L20

     FILE 'REGISTRY' ENTERED AT 07:05:22 ON 28 JUL 1999
```

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 07:06:40 ON 28 JUL 1999
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1999 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1967 - 28 Jul 1999  VOL 131 ISS 5
FILE LAST UPDATED: 28 Jul 1999  (19990728/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

 This file supports REGlstRY for direct browsing and searching of
 all substance data from the REGISTRY file.  Enter HELP FIRST for
 more information.

=> d l47 bib abs hitrn tot

L47  ANSWER 1 OF 10  HCAPLUS  COPYRIGHT 1999 ACS
AN   1999:425747  HCAPLUS
DN   131:54018
TI   Combination of benzocycloheptapyridine compound farnesyl protein
     transferase inhibitors and antineoplastic drugs for treating proliferative
     diseases
IN   Bishop, Walter R.; Catino, Joseph J.; Doll, Ronald J.; Ganguly, Ashit;
     Girijavallabhan, Viyyoor; Kirschmeier, Paul; Liu, Ming; Nielsen, Loretta
     L.; Cutler, David L.
PA   Schering Corporation, USA
SO   PCT Int. Appl., 220 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 9932114         A1   19990701       WO 98-US26224    19981221
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK,
             EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ,
             LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO,
             RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
             CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRAI US 97-996027     19971222
     US 98-143529     19980828
     US 98-181969     19981029
AB   Methods are provided for treating proliferative diseases, esp. cancers,
     comprising administering a farnesyl protein transferase inhibitor in
     conjunction with an antineoplastic agent and/or radiation therapy.
IT   23214-92-8, Doxorubicin 56420-45-2, Epirubicin
     RL: BAC (Biological activity or effector, except adverse); THU
```

(Therapeutic use); BIOL (Biological study); USES (Uses)
(farnesyl protein transferase inhibitor combination with antineoplastic drug or radiotherapy for treatment of proliferative disease)

L47 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 1999 ACS
AN 1999:90333 HCAPLUS
DN 130:167157
TI **Oligopeptides** recognized and cleavable by free **prostate** specific antigen for treating **prostate** cancer
IN **Defeo-Jones, Deborah; Garsky, Victor M.; Feng, Dong-Mei; Jones, Raymond E.; Oliff, Allen I.**
PA **Merck** and Co., Inc., USA
SO U.S., 100 pp., Cont.-in-part of U.S. Ser. No. 468,161.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5866679	A	19990202	US 95-540412	19951006
	US 5599686	A	19970204	US 94-267092	19940628
	WO 9712624	A1	19970410	WO 96-US15713	19961002
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2233272	AA	19970410	CA 96-2233272	19961002
	AU 9672034	A1	19970428	AU 96-72034	19961002
	EP 853483	A1	19980722	EP 96-933210	19961002
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 10512588	T2	19981202	JP 96-514360	19961002

PRAI US 94-267092 19940628
US 95-404833 19950315
US 95-468161 19950606
US 95-540412 19951006
WO 96-US15713 19961002
OS MARPAT 130:167157
AB **Oligopeptides** which comprise amino acid sequences that are recognized and proteolytically cleaved by free **prostate** specific antigen (PSA) are described. Also described are assays which comprise such **oligopeptides** useful for detg. free PSA protease activity in vitro and in vivo. Therapeutic agents which comprise conjugates of such **oligopeptides** and known therapeutic or cytotoxic agents are also described. The **oligopeptide** conjugates are useful for treatment of **prostate** cancer.
IT **174640-93-8 189509-93-1 189509-96-4 189509-98-6 189510-00-7 189510-02-9 189510-04-1 189510-18-7 189510-22-3 189510-41-6 189510-44-9 189510-46-1 189510-49-4 189510-54-1 189510-58-5 189510-60-9 189510-62-1 189510-64-3 189510-66-5 189510-68-7 189510-70-1 189510-72-3 189510-74-5 189510-76-7 189510-78-9 189510-80-3 189510-82-5 189510-84-7 189512-66-1 189512-69-4 189512-70-7 189512-71-8 189512-72-9**

189512-74-1 189512-82-1 189512-85-4
189513-11-9 189513-14-2
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**oligopeptides** recognized and cleavable by free **prostate** specific antigen protease and conjugates with cytotoxic agent for treating **prostate** cancer)

IT **189513-04-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(**oligopeptides** recognized and cleavable by free **prostate** specific antigen protease and conjugates with cytotoxic agent for treating **prostate** cancer)

IT **23214-92-8DP, Doxorubicin**, conjugates
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**oligopeptides** recognized and cleavable by free **prostate** specific antigen protease and conjugates with cytotoxic agent for treating **prostate** cancer)

IT **174640-92-7P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**oligopeptides** recognized and cleavable by free **prostate** specific antigen protease and conjugates with cytotoxic agent for treating **prostate** cancer)

IT **59-05-2D, Methotrexate**, conjugates **865-21-4D, Vinblastine**, conjugates
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**oligopeptides** recognized and cleavable by free **prostate** specific antigen protease and conjugates with cytotoxic agent for treating **prostate** cancer)

L47 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 1999 ACS
AN 1998:789167 HCAPLUS
DN 130:25350
TI Preparation of tissue specific peptide prodrugs
IN Issacs, John T.; Denmeade, Samuel R.; Christensen, S. Brogger; Lilja, Hans
PA The Johns Hopkins University School of Medecine, USA
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9852966	A1	19981126	WO 98-US10285	19980519
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9875822	A1	19981211	AU 98-75822	19980519
PRAI	US 97-47070	19970519			
	US 98-80046	19980330			
	WO 98-US10285	19980519			

OS MARPAT 130:25350
GI



I



II

AB Peptides, X5X4X3X2X1 [X5 = 0 - 16 amino acids; X4 = serine, isoleucine, lysine; X3 = serine, lysine; X2 = leucine, tyrosine, lysine; X1 = glutamine, asparagine, tyrosine], which contain cleavage sites specifically cleaved by **prostate** specific antigen (PSA), were prepd. Thus, H-Glu-His-Ser-Ser-Lys-Leu-Gln-OH was prepd. and cleavage rate by PSA was detd. Prodrug compns. which comprise a therapeutic drug linked to a peptide contg. a PSA specific cleavage site were also described. Upon cleavage of the prodrug by PSA, the therapeutic drugs are activated and exert their toxicity. Novel thapsigargin based sesquiterpene-.gamma.-lactones I [R1 = alkanoyl, alkenoyl, arenoyl; R2 = alkanoyl or alkenoyl or arenoyl contg. a primary amine; R3 = alkanoyl, alkenoyl] were prepd. to be linked to carrier moieties of the peptide. Thus, lactone II was prepd. by esterification of 8-O-debutanoylthapsigargin with pimelic acid followed by amidation with 2,4-diaminotoluene. Cytotoxicity and sarco/endoplasmic reticulum calcium ATPase (SERCA) assays of the prepd. thapsigargin analogs were preformed with II producing 50% inhibition of Ca uptake at 17.7.+-.2.4 nM. Methods for treating cell proliferative disorders are also described.

IT **210888-63-4P 210888-64-5P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tissue specific peptide prodrugs)

IT **23214-92-8D, Doxorubicin**, peptidyl prodrugs
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of tissue specific peptide prodrugs)

IT **70774-25-3**
RL: RCT (Reactant)
(prepn. of tissue specific peptide prodrugs)

L47 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 1999 ACS
AN 1998:402057 HCAPLUS

DN 129:144610
TI Enzymic activation of a **doxorubicin**-peptide prodrug by **prostate**-specific antigen
AU Denmeade, Samuel R.; Nagy, Attila; Gao, Jin; Lilja, Hans; Schally, Andrew V.; Isaacs, John T.
CS Johns Hopkins Oncology Center, Johns Hopkins School of Medicine, Baltimore, MD, 21231 - 1001, USA
SO Cancer Res. (1998), 58(12), 2537-2540
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
AB New approaches to target cytotoxic therapy specifically to metastatic **prostate** cancer sites are urgently needed. As such an approach, an inactive prodrug was synthesized by coupling the primary amine of **doxorubicin** to the COOH-terminal carboxyl of a seven-amino acid peptide carrier (i.e., Mu-His-Ser-Ser-Lys-Leu-Gln-Leu). The seven-amino acid peptide was documented to be hydrolyzable specifically by the serine protease **prostate**-specific antigen (PSA) to liberate the active cytotoxin L-leucyl-**doxorubicin**. Primary cultures of PC-82 human **prostate** cancer cells secreted high levels of enzymically active PSA (i.e., 70 .+-. 5 ng of enzymically active PSA/106 cells/24 h), whereas LNCaP human **prostate** cancer cells produced lower levels of enzymically active PSA (i.e., 2.3 .+-. 1 ng/106 cells/24 h). LNCaP cells, however, secreted sufficient amts. of enzymically active PSA to activate the **doxorubicin** prodrug to a cytotoxic form in vitro. The specificity of the cytotoxic response to the prodrug was demonstrated by the fact that 70 nM of the prodrug killed 50% of the PSA-producing LNCaP cells, whereas doses as high as 1 .mu.M had no cytotoxic effect on PSA-nonproducing TSU human **prostate** cancer cells in vitro.
IT **70774-25-3**, L-Leucyl-**doxorubicin**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(enzymic activation of a **doxorubicin**-peptide prodrug by **prostate**-specific antigen)
IT **23214-92-8**, **Doxorubicin**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(enzymic activation of a **doxorubicin**-peptide prodrug by **prostate**-specific antigen)
IT **210888-63-4P 210888-64-5P**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(enzymic activation of a **doxorubicin**-peptide prodrug by **prostate**-specific antigen)

L47 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 1999 ACS
AN 1998:293399 HCAPLUS
DN 129:4866
TI Peptide conjugates useful in the treatment of **prostate** cancer
IN **Garsky, Victor M.; Feng, Dong-Mei; Defeo-Jones, Deborah**
PA **Merck** & Co., Inc., USA; Garsky, Victor M.; Feng, Dong-Mei; Defeo-Jones, Deborah
SO PCT Int. Appl., 143 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9818493	A2	19980507	WO 97-US19225	19971027
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9851497	A1	19980522	AU 98-51497	19971027
PRAI	US 96-29224	19961030			
	GB 96-26309	19961218			
	US 97-42921	19970404			
	GB 97-18160	19970828			
	WO 97-US19225	19971027			

OS MARPAT 129:4866
AB Chem. conjugates which comprise **oligopeptides**, having amino acid sequences that are selectively proteolytically cleaved by free **prostate** specific antigen (PSA), and known cytotoxic agents are disclosed. Such conjugates are useful in the treatment of **prostatic** cancer and benign **prostatic** hypertrophy. Thus, [N-Ac-(4-trans-L-Hyp)]-Ala-Ser-Chg-Gln-Ser-Leu-Dox (L-Hyp = 4-hydroxy-L-proline, Chg = cyclohexylglycine, Dox = **doxorubicin**), prepd. by the solid-phase method, was assayed for in vitro cytotoxicity (LNCaP cell kill in 72 h, EC 50 = 100 .mu.M).
IT **59-05-2DP, Methotrexate**, peptide conjugates
865-21-4DP, Vinblastine, peptide conjugates
23214-92-8DP, Doxorubicin, peptide conjugates
207395-84-4P 207395-85-5P 207395-86-6P
207395-94-6P 207396-04-1P 207396-05-2P
207396-06-3P 207396-07-4P 207396-08-5P
207396-09-6P 207396-10-9P 207396-11-0P
207396-12-1P 207396-13-2P 207396-14-3P
207396-15-4P 207396-16-5P 207396-17-6P
207396-18-7P 207401-71-6P 207401-72-7P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptide conjugates useful in treatment of **prostate** cancer)
IT **207395-90-2P 207395-93-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(peptide conjugates useful in treatment of **prostate** cancer)

L47 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 1999 ACS
AN 1998:180735 HCAPLUS
DN 128:252982
TI **Oligopeptide**-cytotoxic agent conjugates useful in the treatment of **prostate** cancer and benign **prostatic** hypertrophy
IN **Feng, Dong-Mei; Garsky, Victor M.; Jones, Raymond E.; Oliff, Allen I.**; Wai, Jenny M.
PA **Merck** & Co., Inc., USA; Feng, Dong-Mei; Garsky, Victor M.; Jones, Raymond E.; Oliff, Allen I.; Wai, Jenny M.
SO PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9810651	A1	19980319	WO 97-US16087	19970910
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9744123	A1	19980402	AU 97-44123	19970910
	EP 926955	A1	19990707	EP 97-942423	19970910
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				

PRAI US 96-26015 19960912
GB 96-24170 19961119
WO 97-US16087 19970910
OS MARPAT 128:252982
AB Chem. conjugates are disclosed which comprise **oligopeptides**, having amino acid sequences that are selectively proteolytically cleaved by free **prostate** specific antigen (PSA), hydrophilic **oligopeptide** blocking groups, and known cytotoxic agents. Such conjugates are useful in the treatment of **prostatic** cancer and benign **prostatic** hypertrophy (BPH).
IT **205184-64-1P 205184-67-4P 205184-71-0P**
205184-74-3P 205184-81-2P 205184-84-5P
205184-87-8P 205184-90-3P 205184-93-6P
205184-96-9P 205184-99-2P 205185-02-0P
205185-07-5P 205185-10-0P 205185-15-5P
205185-19-9P 205185-23-5P 205185-26-8P
205185-30-4P 205185-33-7P 205185-35-9P
205185-41-7P 205185-44-0P 205185-48-4P
205185-54-2P 205185-59-7P 205185-64-4P
205185-67-7P 205185-70-2P 205185-73-5P
205185-76-8P 205185-80-4P 205185-83-7P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**oligopeptide**-cytotoxic agent conjugates for treatment of **prostate** cancer and benign **prostatic** hypertrophy)
IT **59-05-2D, Methotrexate, oligopeptide** conjugates **865-21-4D, Vinblastine, oligopeptide** conjugates **23214-92-8D, Doxorubicin, oligopeptide** conjugates **205184-64-1D**, optical isomers **205184-67-4D**, optical isomers **205184-71-0D**, optical isomers **205184-74-3D**, optical isomers **205184-77-6 205184-77-6D**, optical isomers **205184-81-2D**, optical isomers **205184-84-5D**, optical isomers **205184-87-8D**, optical isomers **205184-90-3D**, optical isomers **205184-93-6D**, optical isomers **205184-96-9D**, optical isomers **205184-99-2D**, optical isomers **205185-02-0D**, optical isomers **205185-07-5D**, optical isomers **205185-10-0D**, optical isomers **205185-15-5D**, optical isomers **205185-19-9D**, optical isomers **205185-23-5D**, optical isomers **205185-26-8D**, optical isomers **205185-30-4D**, optical isomers **205185-33-7D**, optical isomers **205185-35-9D**, optical isomers **205185-41-7D**, optical isomers **205185-44-0D**,

optical isomers **205185-48-4D**, optical isomers **205185-54-2D**, optical isomers **205185-59-7D**, optical isomers **205185-64-4D**, optical isomers **205185-67-7D**, optical isomers **205185-70-2D**, optical isomers **205185-73-5D**, optical isomers **205185-76-8D**, optical isomers **205185-80-4D**, optical isomers **205185-83-7D**, optical isomers **205185-86-0 205185-86-0D**, optical isomers **205185-88-2 205185-88-2D**, optical isomers **205185-89-3 205185-89-3D**, optical isomers
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**oligopeptide**-cytotoxic agent conjugates for treatment of **prostate** cancer and benign **prostatic** hypertrophy)

IT **23214-92-8, Doxorubicin**
RL: RCT (Reactant)
(reaction; **oligopeptide**-cytotoxic agent conjugates for treatment of **prostate** cancer and benign **prostatic** hypertrophy)

L47 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 1999 ACS
AN 1997:374825 HCAPLUS
DN 126:343882
TI Preparation of peptide conjugates useful in the treatment of benign **prostatic** hyperplasia
IN **Defeo-Jones, Deborah; Jones, Raymond E.; Oliff, Allen I.**; Scolnick, Edward M.; **Garsky, Victor M.**
PA **Merck** and Co., Inc., USA; Defeo-Jones, Deborah; Jones, Raymond E.; Oliff, Allen I.; Scolnick, Edward M.; Garsky, Victor M.
SO PCT Int. Appl., 193 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9714416	A1	19970424	WO 96-US16490	19961015
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9674321	A1	19970507	AU 96-74321	19961015
	EP 855910	A1	19980805	EP 96-936504	19961015
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				

PRAI US 95-5664 19951018
GB 96-2903 19960213
WO 96-US16490 19961015
OS MARPAT 126:343882
AB Novel pharmaceutical compns. useful for the treatment of benign **prostatic** hyperplasia which comprises novel **oligopeptides**, which are selectively cleaved by enzymically active **prostate** specific antigen (PSA), in conjunction with a cytotoxic agent are described. Methods of treating benign **prostate** hypertrophy are also disclosed. Thus, **doxorubicin** (Dox) conjugate Ac-Lys-Tyr-Gln-Ser-Ser-Ser-Leu-Dox was prepd. and assayed for recognition by free PSA (98% cleavage after 4 h).
IT **59-05-2DP, Methotrexate**, peptide conjugates

865-21-4DP, Vinblastine, peptide conjugates
23214-92-8DP, peptide conjugates **123165-35-5P**
174640-89-2P 174640-90-5P 189509-93-1P
189510-41-6P 189510-44-9P 189510-46-1P
189510-54-1P 189510-62-1P 189510-64-3P
189510-66-5P 189510-68-7P 189510-70-1P
189510-74-5P 189510-76-7P 189510-78-9P
189510-80-3P 189512-66-1P 189512-68-3P
189512-69-4P 189512-70-7P 189512-71-8P
189512-72-9P 189512-73-0P 189512-74-1P
189512-76-3P 189512-78-5P 189512-79-6P
189512-80-9P 189512-81-0P 189512-82-1P
189512-85-4P 189512-87-6P 189512-90-1P
189512-91-2P 189512-92-3P 189512-93-4P
189512-94-5P 189512-95-6P 189512-96-7P
189512-97-8P 189513-11-9P 189513-13-1P
189513-14-2P 189513-16-4P 189513-18-6P
189513-20-0P 189513-22-2P 189513-23-3P
189808-94-4P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptide conjugates for treatment of benign **prostatic** hyperplasia)

IT **23214-92-8**
RL: RCT (Reactant)
(prepn. of peptide conjugates for treatment of benign **prostatic** hyperplasia)

IT **189513-04-0P 189513-09-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of peptide conjugates for treatment of benign **prostatic** hyperplasia)

IT **123105-77-1P 174640-84-7P 174640-85-8P**
174640-86-9P 174640-87-0P 174640-88-1P
174640-91-6P 174640-92-7P 174640-93-8P
189508-81-4P 189508-83-6P 189509-96-4P
189509-98-6P 189510-00-7P 189510-02-9P
189510-04-1P 189510-18-7P 189510-22-3P
189510-49-4P 189510-58-5P 189510-60-9P
189510-72-3P 189510-82-5P 189510-84-7P
189513-24-4P 189513-25-5P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptide conjugates for treatment of benign **prostatic** hyperplasia)

L47 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 1999 ACS
AN 1997:369645 HCAPLUS
DN 126:343876
TI Novel peptides for treatment of **prostate** cancer
IN **Defeo-Jones, Deborah; Feng, Dong-mei; Garsky, Victor M.; Jones, Raymond E.; Oliff, Allen I.**
PA **Merck** and Co., Inc., USA; Defeo-Jones, Deborah; Feng, Dong-Mei; Garsky, Victor M.; Jones, Raymond E.; Oliff, Allen I.
SO PCT Int. Appl., 188 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9712624	A1	19970410	WO 96-US15713	19961002
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5866679	A	19990202	US 95-540412	19951006
	AU 9672034	A1	19970428	AU 96-72034	19961002
	EP 853483	A1	19980722	EP 96-933210	19961002
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 10512588	T2	19981202	JP 96-514360	19961002
PRAI	US 95-540412	19951006			
	US 94-267092	19940628			
	US 95-404833	19950315			
	US 95-468161	19950606			
	WO 96-US15713	19961002			

OS MARPAT 126:343876

AB **Oligopeptides** which comprise amino acid sequences that are recognized and proteolytically cleaved by free **prostate** specific antigen (PSA) are described. Also described are assays which comprise such **oligopeptides** useful for detg. free PSA protease activity in vitro and in vivo. Therapeutic agents which comprise conjugates of such **oligopeptides** and known cytotoxic agents are also described. Thus, **doxorubicin** (Dox) conjugate Ac-Lys-Tyr-Gln-Ser-Ser-Ser-Leu-Dox was prepd. and assayed for recognition by free PSA (98% cleavage after 4 h).

IT **123165-35-5P 174640-89-2P 174640-90-5P**
189509-93-1P 189510-41-6P 189510-44-9P
189510-46-1P 189510-54-1P 189510-62-1P
189510-64-3P 189510-66-5P 189510-68-7P
189510-70-1P 189510-74-5P 189510-76-7P
189510-78-9P 189510-80-3P 189512-66-1P
189512-68-3P 189512-69-4P 189512-70-7P
189512-71-8P 189512-72-9P 189512-73-0P
189512-74-1P 189512-76-3P 189512-78-5P
189512-79-6P 189512-80-9P 189512-81-0P
189512-82-1P 189512-85-4P 189512-87-6P
189512-90-1P 189512-91-2P 189512-92-3P
189512-93-4P 189512-94-5P 189512-95-6P
189512-96-7P 189512-97-8P 189513-11-9P
189513-13-1P 189513-14-2P 189513-16-4P
189513-18-6P 189513-20-0P 189513-22-2P
189513-23-3P 189808-94-4P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptides for treatment of **prostate** cancer)

IT **23214-92-8**
RL: RCT (Reactant)
(peptides for treatment of **prostate** cancer)

IT **189513-04-0P 189513-09-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(peptides for treatment of **prostate** cancer)

IT **123105-77-1P 174640-84-7P 174640-85-8P**
174640-86-9P 174640-87-0P 174640-88-1P

174640-91-6P 174640-92-7P 174640-93-8P
189508-81-4P 189508-83-6P 189509-96-4P
189509-98-6P 189510-00-7P 189510-02-9P
189510-04-1P 189510-18-7P 189510-22-3P
189510-49-4P 189510-58-5P 189510-60-9P
189510-72-3P 189510-82-5P 189510-84-7P
189513-24-4P 189513-25-5P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptides for treatment of **prostate** cancer)

L47 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 1999 ACS
AN 1996:177894 HCAPLUS
DN 124:220505
TI Novel **oligopeptides** for diagnosis and treatment of **prostate** cancer
IN **DeFeo-Jones, Deborah; Feng, Dong-Mei; Garsky, Victor M.; Jones, Raymond E.; Oliff, Allen I.**
PA **Merck** and Co., Inc., USA
SO PCT Int. Appl., 141 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9600503	A1	19960111	WO 95-US8156	19950607
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, US, UZ				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5599686	A	19970204	US 94-267092	19940628
	CA 2192957	AA	19960111	CA 95-2192957	19950607
	AU 9530922	A1	19960125	AU 95-30922	19950607
	AU 689934	B2	19980409		
	EP 771209	A2	19970507	EP 95-926602	19950607
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1156964	A	19970813	CN 95-194855	19950607
	HU 76350	A2	19970828	HU 96-3564	19950607
	JP 10502619	T2	19980310	JP 95-503422	19950607
	FI 9605225	A	19970226	FI 96-5225	19961227
	NO 9605592	A	19970228	NO 96-5592	19961227

PRAI US 94-267092 19940628
US 95-404833 19950315
WO 95-US8156 19950607
OS MARPAT 124:220505
AB **Oligopeptides** that are recognized and proteolytically cleaved by free **prostate** specific antigen (PSA) are provided. Such **oligopeptides** are useful for detg. free PSA protease activity in vitro and in vivo for monitoring the treatment of adenocarcinoma of protease,. Therapeutic agents which comprise conjugates of such **oligopeptides** and known cytotoxic agents are also described.
IT **174640-78-9P 174640-79-0P 174640-80-3P**
174640-81-4P 174640-82-5P 174640-83-6P
174640-84-7P 174640-85-8P 174640-86-9P
174640-87-0P 174640-88-1P 174640-89-2P
174640-90-5P 174640-91-6P 174640-92-7P

174640-93-8P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**doxorubicin** conjugates with **oligopeptide** substrate of free **prostate** specific antigen; treatment of **prostate** cancer using)

IT **59-05-2D, Methotrexate**, conjugates with **oligopeptide** substrate of free **prostate** specific antigen
865-21-4D, Vinblastine, conjugates with **oligopeptide** substrate of free **prostate** specific antigen
23214-92-8D, Doxorubicin, conjugates with **oligopeptide** substrate of free **prostate** specific antigen
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of **prostate** cancer using)

L47 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 1999 ACS
AN 1993:509327 HCAPLUS
DN 119:109327
TI Short-chain analogs of luteinizing hormone-releasing hormone containing cytotoxic moieties
AU Janaky, T.; Juhasz, A.; Rekasi, Z.; Serfozo, P.; Pinski, J.; Bokser, L.; Srkalovic, G.; Milovanovic, S.; Redding, T. W.; et al.
CS Sch. Med., Tulane Univ., New Orleans, LA, 70146, USA
SO Proc. Natl. Acad. Sci. U. S. A. (1992), 89(21), 10203-7
CODEN: PNASA6; ISSN: 0027-8424
DT Journal
LA English
AB Five hexapeptide and heptapeptide analogs of LH-RH were synthesized for use as carriers for cytotoxic compds. These short analogs were expected to enhance target selectivity of the antineoplastic agents linked to them. Native LH-RH-(3-9) and LH-RH-(4-9) contg. D-lysine and D-ornithine at position 6 were amidated with ethylamine and acylated on the N terminus. The receptor-binding affinity of one hexapeptide carrier AJ-41 (Ac-Ser-Tyr-D-Lys-Leu-Arg-Pro-NH-Et) to human breast cancer cell membranes was similar to that of [D-Trp6]LH-RH. Alkylating N mustards (melphalan, Ac-melphalan), anthraquinone derivs. including anticancer antibiotic **doxorubicin**, antimetabolite (**methotrexate**), and cisplatin-like platinum complex were linked to these peptides through their .omega.-amino group at position 6. The hybrid mols. showed no LH-RH agonistic activity in vitro and in vivo but had nontypical antagonistic effects on pituitary cells in vitro at the doses tested. These analogs showed a wide range of receptor-binding affinities to rat pituitaries and cell membranes of human breast cancer and rat Dunning **prostate** cancer. Several of these conjugates exerted some cytotoxic effects on MCF-7 breast cancer cell line.

IT **148218-99-9**
RL: PRP (Properties)
(LH-RH receptor binding affinity of, in human breast cancer and rat pituitary gland)

IT **59-05-2D**, MTX, coupled with LH-RH analogs **23214-92-8D**, coupled with LH-RH analogs
RL: BIOL (Biological study)
(anticancer activity and HPLC capacity factor and LH-RH receptor binding activity of)

=> fil reg
FILE 'REGISTRY' ENTERED AT 07:07:06 ON 28 JUL 1999
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 28 JUL 99 HIGHEST RN 229185-84-6
DICTIONARY FILE UPDATES: 28 JUL 99 HIGHEST RN 229185-84-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 13, 1999

Please note that search-term pricing does apply when conducting SmartSELECT searches.

=> d ide can 134

L34 ANSWER 1 OF 1 REGISTRY COPYRIGHT 1999 ACS
RN 23214-92-8 REGISTRY
CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-
OTHER NAMES:
CN 14-Hydroxydaunomycin
CN Adriablastin
CN Doxil
CN **Doxorubicin**
CN FI 106
CN NSC 123127
FS STEREOSEARCH
DR 24385-08-8, 25311-50-6, 23257-17-2, 29042-30-6
MF C27 H29 N O11
CI COM
LC STN Files: ADISINSIGHT, AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CEN, CHEMLIST, CBNB, CIN, CSCHEM, CSNB, DDFU, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PROMT, RTECS*, TOXLINE, TOXLIT, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



9418 REFERENCES IN FILE CA (1967 TO DATE)
646 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
9434 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 131:63485

REFERENCE 2: 131:63351

REFERENCE 3: 131:57138

REFERENCE 4: 131:56185

REFERENCE 5: 131:55873

REFERENCE 6: 131:54018

REFERENCE 7: 131:53984

REFERENCE 8: 131:53692

REFERENCE 9: 131:53679

REFERENCE 10: 131:53658

=> d ide can 135

L35 ANSWER 1 OF 1 REGISTRY COPYRIGHT 1999 ACS
RN 59-05-2 REGISTRY
CN L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Glutamic acid, N-[p-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-, L-(+)- (8CI)
OTHER NAMES:
CN (+)-Amethopterin
CN 4-Amino-10-methylfolic acid
CN 4-Amino-N10-methylfolic acid
CN 4-Amino-N10-methylpteroylglutamic acid
CN Amethopterin
CN Amethopterine
CN Antifolan
CN CL 14377
CN L-Amethopterin
CN L-Methotrexate
CN **Methotrexate**
CN MTX
CN NSC 740
CN R 9985
FS STEREOSEARCH
MF C20 H22 N8 O5
CI COM
LC STN Files: ADISINSIGHT, AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMLIST, CBNB, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



7654 REFERENCES IN FILE CA (1967 TO DATE)
590 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
7667 REFERENCES IN FILE CAPLUS (1967 TO DATE)
73 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 131:63485

REFERENCE 2: 131:63339

REFERENCE 3: 131:57536

REFERENCE 4: 131:57126

REFERENCE 5: 131:54018

REFERENCE 6: 131:53703

REFERENCE 7: 131:53658

REFERENCE 8: 131:53622

REFERENCE 9: 131:53471

REFERENCE 10: 131:49486

=> d ide can l36

L36 ANSWER 1 OF 1 REGISTRY COPYRIGHT 1999 ACS
RN 865-21-4 REGISTRY
CN Vincaleukoblastine (6CI, 8CI, 9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Indolizino[8,1-cd]carbazole, vincaleukoblastine deriv.
CN 2H-3,7-Methanoazacycloundecino[5,4-b]indole, vincaleukoblastine deriv.
CN **Vinblastine (7CI)**
OTHER NAMES:
CN 1H-Indolizino[8,1-cd]carbazole-5-carboxylic acid, 4-(acetyloxy)-3a-ethyl-9-[5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino[5,4-b]indol-9-yl]-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-, methyl ester, [3aR-[3a.alpha.,4.beta.,5.beta.,5a.beta.,9(3R*,5S*,7R*,9S*),10bR*,13a.alpha.]]-
CN Rozevin
CN Vinblastin
CN Vincaleucoblastin

CN Vincaleucoblastine
CN VLB
CN [3aR-[3a.alpha.,4.beta.,5.beta.,5a.beta.,9(3R*,5S*,7R*,9S*),10bR*,13a.alpha.]]-Methyl 4-(acetyloxy)-3a-ethyl-9-[5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino[5,4-b]indol-9-yl]-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-1H-indolizino[8,1-cd]carbazole-5-carboxylate
FS STEREOSEARCH
DR 7060-58-4, 57-23-8
MF C46 H58 N4 O9
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



3074 REFERENCES IN FILE CA (1967 TO DATE)
93 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3076 REFERENCES IN FILE CAPLUS (1967 TO DATE)
10 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 131:63485

REFERENCE 2: 131:54018

REFERENCE 3: 131:53705

REFERENCE 4: 131:53596

REFERENCE 5: 131:49486

REFERENCE 6: 131:39760

REFERENCE 7: 131:39204

REFERENCE 8: 131:27948

REFERENCE 9: 131:27947

REFERENCE 10: 131:27587

list cmpds from rep 1-10, L47

=> d ide can l52 tot

L52 ANSWER 1 OF 8 REGISTRY COPYRIGHT 1999 ACS
RN **189513-25-5** REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[(N-acetyl-L-alanyl-L-alanyl-L-alanyl)amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C38 H46 N4 O15
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:343882

REFERENCE 2: 126:343876

L52 ANSWER 2 OF 8 REGISTRY COPYRIGHT 1999 ACS
RN **189513-24-4** REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[[(2S)-2-(acetylamino)-1-oxopropyl]amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H36 N2 O13
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:343882

REFERENCE 2: 126:343876

L52 ANSWER 3 OF 8 REGISTRY COPYRIGHT 1999 ACS
RN **189513-22-2** REGISTRY
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[(methylamino)acetyl]amino]-.alpha.-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)-, monoacetate (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H34 N2 O12 . C2 H4 O2
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 189513-21-1
CMF C30 H34 N2 O12

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:343882

REFERENCE 2: 126:343876

L52 ANSWER 4 OF 8 REGISTRY COPYRIGHT 1999 ACS
RN **189513-20-0** REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[[(2S)-2-amino-4-(methylthio)-1-oxobutyl]amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-, monoacetate (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H38 N2 O12 S . C2 H4 O2
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 189513-19-7
CMF C32 H38 N2 O12 S

Absolute stereochemistry.



CM 2

CRN 64-19-7

CMF C2 H4 O2



2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:343882

REFERENCE 2: 126:343876

L52 ANSWER 5 OF 8 REGISTRY COPYRIGHT 1999 ACS
RN **189513-18-6** REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[(2-amino-2-methyl-1-oxopropyl)amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-, monoacetate (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H36 N2 O12 . C2 H4 O2
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 189513-17-5
CMF C31 H36 N2 O12

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:343882

REFERENCE 2: 126:343876

L52 ANSWER 6 OF 8 REGISTRY COPYRIGHT 1999 ACS
RN **123165-35-5** REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[(aminoacetyl)amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-, monoacetate (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H32 N2 O12 . C2 H4 O2
SR CA
LC STN Files: CA, CAPLUS, TOXLIT

CM 1

CRN 123105-76-0
CMF C29 H32 N2 O12

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:343882

REFERENCE 2: 126:343876

REFERENCE 3: 111:187593

L52 ANSWER 7 OF 8 REGISTRY COPYRIGHT 1999 ACS
RN **123105-77-1** REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[(2-amino-1-oxopropyl)amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, [8S-[8.alpha.,10.alpha.(R*)]]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H34 N2 O12
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXLIT

Absolute stereochemistry.



3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:343882

REFERENCE 2: 126:343876

REFERENCE 3: 111:187593

L52 ANSWER 8 OF 8 REGISTRY COPYRIGHT 1999 ACS
RN **70774-25-3** REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[[(2S)-2-amino-4-methyl-1-oxopentyl]amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5,12-Naphthacenedione, 10-[[3-[(2-amino-4-methyl-1-oxopentyl)amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-

trihydroxy-8-(hydroxyacetyl)-1-methoxy-, [8S-[8.alpha.,10.alpha.(R*)]]-
OTHER NAMES:
CN L-Leucyldoxorubicin
CN Leurubicin
CN N-L-Leucyldoxorubicin
FS STEREOSEARCH
MF C33 H40 N2 O12
CI COM
LC STN Files: ADISINSIGHT, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CANCERLIT, CAPLUS, DDFU, DRUGU, EMBASE, IPA, MEDLINE, TOXLINE, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



20 REFERENCES IN FILE CA (1967 TO DATE)
20 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:75865

REFERENCE 2: 130:25350

REFERENCE 3: 129:144610

REFERENCE 4: 125:237763

REFERENCE 5: 125:49345

REFERENCE 6: 120:152912

REFERENCE 7: 119:262111

REFERENCE 8: 119:62595

REFERENCE 9: 118:139397

REFERENCE 10: 117:103474

=> d reg tot 151
1 RN **210888-64-5** REGISTRY

2	RN	210888-63-4	REGISTRY
3	RN	207401-72-7	REGISTRY
4	RN	207401-71-6	REGISTRY
5	RN	207396-18-7	REGISTRY
6	RN	207396-17-6	REGISTRY
7	RN	207396-16-5	REGISTRY
8	RN	207396-15-4	REGISTRY
9	RN	207396-14-3	REGISTRY
10	RN	207396-13-2	REGISTRY
11	RN	207396-12-1	REGISTRY
12	RN	207396-11-0	REGISTRY
13	RN	207396-10-9	REGISTRY
14	RN	207396-09-6	REGISTRY
15	RN	207396-08-5	REGISTRY
16	RN	207396-07-4	REGISTRY
17	RN	207396-06-3	REGISTRY
18	RN	207396-05-2	REGISTRY
19	RN	207396-04-1	REGISTRY
20	RN	207395-94-6	REGISTRY
21	RN	207395-93-5	REGISTRY
22	RN	207395-90-2	REGISTRY
23	RN	207395-86-6	REGISTRY
24	RN	207395-85-5	REGISTRY
25	RN	207395-84-4	REGISTRY
26	RN	205185-89-3	REGISTRY
27	RN	205185-88-2	REGISTRY
28	RN	205185-86-0	REGISTRY
29	RN	205185-83-7	REGISTRY
30	RN	205185-80-4	REGISTRY
31	RN	205185-76-8	REGISTRY
32	RN	205185-73-5	REGISTRY
33	RN	205185-70-2	REGISTRY
34	RN	205185-67-7	REGISTRY
35	RN	205185-64-4	REGISTRY
36	RN	205185-59-7	REGISTRY
37	RN	205185-54-2	REGISTRY
38	RN	205185-48-4	REGISTRY
39	RN	205185-44-0	REGISTRY
40	RN	205185-41-7	REGISTRY
41	RN	205185-35-9	REGISTRY
42	RN	205185-33-7	REGISTRY
43	RN	205185-30-4	REGISTRY
44	RN	205185-26-8	REGISTRY
45	RN	205185-23-5	REGISTRY
46	RN	205185-19-9	REGISTRY
47	RN	205185-15-5	REGISTRY
48	RN	205185-10-0	REGISTRY
49	RN	205185-07-5	REGISTRY
50	RN	205185-02-0	REGISTRY
51	RN	205184-99-2	REGISTRY
52	RN	205184-96-9	REGISTRY
53	RN	205184-93-6	REGISTRY
54	RN	205184-90-3	REGISTRY
55	RN	205184-87-8	REGISTRY
56	RN	205184-84-5	REGISTRY
57	RN	205184-81-2	REGISTRY
58	RN	205184-77-6	REGISTRY
59	RN	205184-74-3	REGISTRY
60	RN	205184-71-0	REGISTRY

- other hit compds
- too many to display
- samples, beginning page 35

61	RN	**205184-67-4**	REGISTRY
62	RN	**205184-64-1**	REGISTRY
63	RN	**189808-94-4**	REGISTRY
64	RN	**189513-16-4**	REGISTRY
65	RN	**189513-14-2**	REGISTRY
66	RN	**189513-13-1**	REGISTRY
67	RN	**189513-11-9**	REGISTRY
68	RN	**189513-09-5**	REGISTRY
69	RN	**189513-04-0**	REGISTRY
70	RN	**189512-97-8**	REGISTRY
71	RN	**189512-96-7**	REGISTRY
72	RN	**189512-95-6**	REGISTRY
73	RN	**189512-94-5**	REGISTRY
74	RN	**189512-93-4**	REGISTRY
75	RN	**189512-92-3**	REGISTRY
76	RN	**189512-91-2**	REGISTRY
77	RN	**189512-90-1**	REGISTRY
78	RN	**189512-87-6**	REGISTRY
79	RN	**189512-85-4**	REGISTRY
80	RN	**189512-82-1**	REGISTRY
81	RN	**189512-81-0**	REGISTRY
82	RN	**189512-80-9**	REGISTRY
83	RN	**189512-79-6**	REGISTRY
84	RN	**189512-78-5**	REGISTRY
85	RN	**189512-76-3**	REGISTRY
86	RN	**189512-74-1**	REGISTRY
87	RN	**189512-73-0**	REGISTRY
88	RN	**189512-72-9**	REGISTRY
89	RN	**189512-71-8**	REGISTRY
90	RN	**189512-70-7**	REGISTRY
91	RN	**189512-69-4**	REGISTRY
92	RN	**189512-68-3**	REGISTRY
93	RN	**189512-66-1**	REGISTRY
94	RN	**189510-84-7**	REGISTRY
95	RN	**189510-82-5**	REGISTRY
96	RN	**189510-80-3**	REGISTRY
97	RN	**189510-78-9**	REGISTRY
98	RN	**189510-76-7**	REGISTRY
99	RN	**189510-74-5**	REGISTRY
100	RN	**189510-72-3**	REGISTRY
101	RN	**189510-70-1**	REGISTRY
102	RN	**189510-68-7**	REGISTRY
103	RN	**189510-66-5**	REGISTRY
104	RN	**189510-64-3**	REGISTRY
105	RN	**189510-62-1**	REGISTRY
106	RN	**189510-60-9**	REGISTRY
107	RN	**189510-58-5**	REGISTRY
108	RN	**189510-54-1**	REGISTRY
109	RN	**189510-49-4**	REGISTRY
110	RN	**189510-46-1**	REGISTRY
111	RN	**189510-44-9**	REGISTRY
112	RN	**189510-41-6**	REGISTRY
113	RN	**189510-22-3**	REGISTRY
114	RN	**189510-18-7**	REGISTRY
115	RN	**189510-04-1**	REGISTRY
116	RN	**189510-02-9**	REGISTRY
117	RN	**189510-00-7**	REGISTRY
118	RN	**189509-98-6**	REGISTRY
119	RN	**189509-96-4**	REGISTRY

120	RN	**189509-93-1**	REGISTRY
121	RN	**189508-83-6**	REGISTRY
122	RN	**189508-81-4**	REGISTRY
123	RN	**174640-93-8**	REGISTRY
124	RN	**174640-92-7**	REGISTRY
125	RN	**174640-91-6**	REGISTRY
126	RN	**174640-90-5**	REGISTRY
127	RN	**174640-89-2**	REGISTRY
128	RN	**174640-88-1**	REGISTRY
129	RN	**174640-87-0**	REGISTRY
130	RN	**174640-86-9**	REGISTRY
131	RN	**174640-85-8**	REGISTRY
132	RN	**174640-84-7**	REGISTRY
133	RN	**174640-83-6**	REGISTRY
134	RN	**174640-82-5**	REGISTRY
135	RN	**174640-81-4**	REGISTRY
136	RN	**174640-80-3**	REGISTRY
137	RN	**174640-79-0**	REGISTRY
138	RN	**174640-78-9**	REGISTRY
139	RN	**148218-99-9**	REGISTRY

=> d l51 ide can 1 3 5 15 26 35 45 55 63 64 75 85 95 105 115 123 128 133 137 139

L51 ANSWER 1 OF 139 REGISTRY COPYRIGHT 1999 ACS
RN **210888-64-5** REGISTRY
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-(4-morpholinylcarbonyl)-L-histidyl-L-seryl-L-seryl-L-lysyl-L-leucyl-L-glutaminyl-L-leucyl]amino]-.alpha.-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)-(9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C67 H95 N13 O23
SR CA
LC STN Files: CA, CAPLUS, TOXLIT

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:25350

REFERENCE 2: 129:144610

L51 ANSWER 3 OF 139 REGISTRY COPYRIGHT 1999 ACS
RN **207401-72-7** REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[[1-(3-carboxy-1-oxopropyl)-3,4-dihydroxyprolyl-L-alanyl-L-seryl-(2S)-2-cyclohexylglycyl-L-glutaminyl-L-seryl-L-leucyl]amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C64 H87 N9 O26
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 129:4866

L51 ANSWER 5 OF 139 REGISTRY COPYRIGHT 1999 ACS
RN **207396-18-7** REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[[(4R)-1-(carboxyacetyl)-4-hydroxy-L-prolyl-L-alanyl-L-seryl-(2S)-2-cyclohexylglycyl-L-glutaminyl-L-seryl-L-leucyl]amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C63 H85 N9 O25
SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 129:4866

L51 ANSWER 15 OF 139 REGISTRY COPYRIGHT 1999 ACS
RN **207396-08-5** REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[[(4R)-1-(4-carboxy-1-oxobutyl)-4-hydroxy-L-prolyl-L-alanyl-L-seryl-(2S)-2-cyclohexylglycyl-L-glutaminyl-L-seryl-L-isoleucyl]amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH
MF C65 H89 N9 O25
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 129:4866

L51 ANSWER 26 OF 139 REGISTRY COPYRIGHT 1999 ACS
RN **205185-89-3** REGISTRY
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[hydroxyacetyl-3-(3-

pyridinyl)-L-alanyl-L-seryl-L-seryl-(2S)-2-cyclohexylglycyl-L-glutaminyl-L-seryl-L-leucyl]amino]-.alpha.-L-lyxo-hexopyranosyl]oxy]-, 1-ether with .alpha.-methyl-.omega.-hydroxypoly(oxy-1,2-ethanediyl), (8S,10S)- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE
MF (C2 H4 O)n C66 H88 N10 O24
CI PMS
PCT Polyether
SR CA
LC STN Files: CA, CAPLUS, TOXLIT

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 128:252982

L51 ANSWER 35 OF 139 REGISTRY COPYRIGHT 1999 ACS
RN **205185-64-4** REGISTRY
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[(2R)-2,3-

dihydroxypropanoyl-L-seryl-L-seryl-(2S)-2-cyclohexylglycyl-L-glutaminyl-L-seryl-L-leucyl]amino]-.alpha.-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH
MF C58 H80 N8 O24
SR CA
LC STN Files: CA, CAPLUS, TOXLIT

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 128:252982

L51 ANSWER 45 OF 139 REGISTRY COPYRIGHT 1999 ACS
RN **205185-23-5** REGISTRY
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[(2S)-2,3-dihydroxypropanoyl-N6-(aminoiminomethyl)-L-lysyl-L-seryl-L-seryl-(2S)-2-cyclohexylglycyl-L-glutaminyl-L-seryl-L-leucyl]amino]-.alpha.-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C65 H94 N12 O25
SR CA
LC STN Files: CA, CAPLUS, TOXLIT

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 128:252982

L51 ANSWER 55 OF 139 REGISTRY COPYRIGHT 1999 ACS

RN **205184-87-8** REGISTRY
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[hydroxyacetyl-N6-(aminoiminomethyl)-L-lysyl-L-alanyl-L-seryl-(2S)-2-cyclohexylglycyl-L-glutaminyl-L-seryl-L-leucyl]amino]-.alpha.-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C64 H92 N12 O23
SR CA
LC STN Files: CA, CAPLUS, TOXLIT

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 128:252982

L51 ANSWER 63 OF 139 REGISTRY COPYRIGHT 1999 ACS
RN **189808-94-4** REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[[N-acetyl-3-(4-aminocyclohexyl)-L-alanyl-L-tyrosyl-L-glutaminyl-L-seryl-L-seryl-L-seryl-L-norleucyl]amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C67 H90 N10 O24
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:343882

REFERENCE 2: 126:343876

L51 ANSWER 64 OF 139 REGISTRY COPYRIGHT 1999 ACS
RN **189513-16-4** REGISTRY
CN L-Norleucinamide, N2-acetyl-L-lysyl-L-tyrosyl-L-glutaminyl-L-seryl-L-seryl-L-seryl-N-[2,3,6-trideoxy-1-O-[(1S,3S)-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1-naphthacenyl]-.alpha.-L-lyxo-hexopyranos-3-yl]-, monoacetate (salt) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C64 H86 N10 O24 . C2 H4 O2
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 189513-15-3
CMF C64 H86 N10 O24

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



CM 2

CRN 64-19-7
CMF C2 H4 O2



2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:343882

REFERENCE 2: 126:343876

L51 ANSWER 75 OF 139 REGISTRY COPYRIGHT 1999 ACS
RN **189512-92-3** REGISTRY
CN L-Norleucinamide, N2-(aminocarbonyl)-N6-(aminoiminomethyl)-L-lysyl-3-iodo-L-tyrosyl-L-glutaminyl-L-seryl-L-seryl-L-seryl-N-[2,3,6-trideoxy-1-O-[(1S,3S)-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1-naphthacenyl]-.alpha.-L-lyxo-hexopyranos-3-yl]- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C64 H86 I N13 O24
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:343882

REFERENCE 2: 126:343876

L51 ANSWER 85 OF 139 REGISTRY COPYRIGHT 1999 ACS
RN **189512-76-3** REGISTRY
CN L-Leucinamide, N-acetyl-L-seryl-L-tyrosyl-L-glutaminyl-L-seryl-L-seryl-L-lysyl-N-[2,3,6-trideoxy-1-O-[(1S,3S)-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1-naphthacenyl]-.alpha.-L-lyxo-hexopyranos-3-yl]-, monoacetate (salt) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C64 H86 N10 O24 . C2 H4 O2
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 189512-75-2
CMF C64 H86 N10 O24

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



CM 2

CRN 64-19-7
CMF C2 H4 O2



2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:343882

REFERENCE 2: 126:343876

L51 ANSWER 95 OF 139 REGISTRY COPYRIGHT 1999 ACS
RN **189510-82-5** REGISTRY
CN L-Norleucinamide, N2-acetyl-N6-(aminoiminomethyl)-L-lysyl-3-fluoro-L-tyrosyl-L-glutaminyl-L-seryl-L-seryl-L-seryl-N-[2,3,6-trideoxy-1-O-[(1S,3S)-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1-naphthacenyl]-.alpha.-L-lyxo-hexopyranos-3-yl]- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C65 H87 F N12 O24
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:167157

REFERENCE 2: 126:343882

REFERENCE 3: 126:343876

L51 ANSWER 105 OF 139 REGISTRY COPYRIGHT 1999 ACS
RN **189510-62-1** REGISTRY
CN L-Leucinamide, N2-acetyl-N6-1H-imidazol-2-yl-L-lysyl-L-tyrosyl-L-glutaminyl-L-seryl-L-seryl-N-[2,3,6-trideoxy-1-O-[(1S,3S)-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1-naphthacenyl]-.alpha.-L-lyxo-hexopyranos-3-yl]- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C64 H83 N11 O22
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:167157

REFERENCE 2: 126:343882

REFERENCE 3: 126:343876

L51 ANSWER 115 OF 139 REGISTRY COPYRIGHT 1999 ACS
RN **189510-04-1** REGISTRY
CN L-Leucinamide, N2-acetyl-L-lysyl-L-alanyl-L-alanyl-L-seryl-L-seryl-L-seryl-N-[2,3,6-trideoxy-1-O-[(1S,3S)-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1-naphthacenyl]-.alpha.-L-lyxo-hexopyranos-3-yl]- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C56 H79 N9 O22
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:167157

REFERENCE 2: 126:343882

REFERENCE 3: 126:343876

L51 ANSWER 123 OF 139 REGISTRY COPYRIGHT 1999 ACS
RN **174640-93-8** REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[(N2-acetyl-L-lysyl-L-tyrosyl-L-glutaminyl-L-seryl-L-seryl-L-norleucyl)amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5,12-Naphthacenedione, 10-[[3-[[N-[N-[N-[N2-[N-(N2-acetyl-L-lysyl)-L-tyrosyl]-L-glutaminyl]-L-seryl]-L-seryl]-L-norleucyl]amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-

FS PROTEIN SEQUENCE; STEREOSEARCH
MF C61 H81 N9 O22
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXLIT, USPATFULL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



4 REFERENCES IN FILE CA (1967 TO DATE)
4 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:167157

REFERENCE 2: 126:343882

REFERENCE 3: 126:343876

REFERENCE 4: 124:220505

L51 ANSWER 128 OF 139 REGISTRY COPYRIGHT 1999 ACS
RN **174640-88-1** REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[(N-acetyl-L-alanyl-L-asparaginyl-L-lysyl-L-alanyl-L-seryl-L-tyrosyl-L-glutaminyl-L-seryl-L-seryl-L-seryl-L-leucyl)amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5,12-Naphthacenedione, 10-[[3-[[N-[N-[N-[N-[N2-[N-[N-[N-[N2-[N2-(N-acetyl-L-alanyl)-L-asparaginyl]-L-lysyl]-L-alanyl]-L-seryl]-L-tyrosyl]-L-glutaminyl]-L-seryl]-L-seryl]-L-seryl]-L-leucyl]amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C77 H107 N15 O30
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXLIT, USPATFULL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:343882

REFERENCE 2: 126:343876

REFERENCE 3: 124:220505

L51 ANSWER 133 OF 139 REGISTRY COPYRIGHT 1999 ACS
RN **174640-83-6** REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[[N-[N-[N-[N-[N-[N2-[N-[N-[N-[N2-(N2-L-alanyl-L-asparaginyl)-L-lysyl]-L-isoleucyl]-L-seryl]-L-tyrosyl]-L-glutaminyl]-L-seryl]-L-seryl]-L-seryl]-L-threonyl]-L-.alpha.-glutamyl]amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C81 H114 N16 O33
SR CA
LC STN Files: CA, CAPLUS, TOXLIT, USPATFULL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 124:220505

L51 ANSWER 137 OF 139 REGISTRY COPYRIGHT 1999 ACS
RN **174640-79-0** REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[[N-[N-[N2-[N-[N-[N-(N2-L-asparaginyl-L-lysyl)-L-isoleucyl]-L-seryl]-L-tyrosyl]-L-glutaminyl]-L-seryl]-L-seryl]amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C66 H90 N12 O25
SR CA
LC STN Files: CA, CAPLUS, TOXLIT, USPATFULL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 124:220505

L51 ANSWER 139 OF 139 REGISTRY COPYRIGHT 1999 ACS
RN **148218-99-9** REGISTRY
CN L-Prolinamide, N-acetyl-L-seryl-L-tyrosyl-N6-[1,5-dioxo-5-[[2,3,6-trideoxy-1-O-[1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1-naphthacenyl]-.alpha.-L-lyxo-hexopyranos-3-yl]amino]pentyl]-D-lysyl-L-leucyl-L-arginyl-N-ethyl-, (1S-cis)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
MF C71 H98 N12 O22
SR CA
LC STN Files: CA, CAPLUS, TOXLIT

PAGE 1-A



PAGE 1-B





PAGE 2-A



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 119:109327